Molecule intelOpportunity: ModerateEssential

Tamoxifen

34 brands · 26 companies · product forms

ATC: L02BA01

Opportunity snapshot

Launch attractiveness
41
Market saturation
68
Price room
100
Regulatory risk
0
34
brands
26
companies
Rs 637.66
median price
26
price points
7.48x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 9%

Price room

Across observed sources and strengths
CheapestRs 148.36
MedianRs 637.66
Most expensiveRs 1,110.06
Spread7.48×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 7.48x across 26 trusted points (Rs 148.36-1110.06). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 9 live products for Tamoxifen — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(32) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

26 canonical companies and 34 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 7.48x across 26 trusted points (Rs 148.36-1110.06). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.